Many countries, including all high-income ones, maintain vital registration systems that provide data on the number of deaths by cause, sex, and age. Some countries also report years of life lost because of premature mortality (YLL) due to each cause, a number that depends on the age of death and on the choice of an algorithm for how YLL should depend on the age of death. The tracking of stillbirths, however, is often incomplete and variable.
As of the early 1990s, no estimates of YLL were available for many developing countries or for regional groupings of such countries. The World Bank (1993) , as part of the preparation for its World Development Report 1993: Investing in Health, initiated an effort to provide estimates of deaths by age and cause, and hence YLL, for around 100 conditions for eight regional groupings, including all low-and middle-income countries. By adding years of healthy life lost as a result of disability (YLD) to YLL, the World Bank was able to generate estimates of the global burden of disease measured both in deaths by cause and in disability-adjusted life-years (DALYs) (Murray, Lopez, and Jamison 1994; World Bank 1993, appendix B) . Murray and Lopez (1997) provide updated and extended results and a complete description of methods. Global burden of disease estimates have subsequently been used to help guide resource allocation in the health sector and to inform debates about national and international disease control priorities (see chapter 1 in this volume); however, the global burden of disease literature currently provides little insight into the importance of deaths near the time of birth.
The purpose of this chapter is to explore the sensitivity of results within the Global Burden of Disease (GBD) framework to alternative approaches to encompassing the large number of deaths that occur near the time of birth, namely almost 4 million neonatal deaths and 3.3 million stillbirths. The sensitivity analyses in this chapter thus complement those of chapter 5, which explore the effect of variations in discount rates, age weights, and disability weights. Chapter 3 in this volume describes the GBD framework and provides estimates of deaths and DALYs by cause for 2001 using the World Bank regional grouping of countries. (Map 1, inside the front cover of this volume, shows the World Bank regional groupings used throughout this book.) This
Chapter 6
Incorporating Deaths Near the Time of Birth Into Estimates of the Global Burden of Disease chapter uses the same framework and numbers to the extent possible, but with the following exceptions:
• We divide the newborn through age 4 category into neonatal (newborn through 27 days), postneonatal (28 days to less than 1 year), and child (1 through 4 years).
• We aggregate the 136 causes noted in chapter 3 into 35 causes.
• We allocate the substantial number of neonatal deaths attributed to pneumonia or sepsis to the chapter 3 category of respiratory infections.
• We explore the sensitivity of the results in chapter 3 to adding stillbirths as a new age category.
• We explore the sensitivity of the results to alternative ways of assigning YLL to deaths under the age of five.
The first section of this chapter deals with mortality: all-cause and cause specific. It uses the results presented in chapter 3, but adds to them estimates of the level of stillbirths and of the level and causes of neonatal mortality. The second section deals with estimation of the burden of disease in DALYs. The inclusion of stillbirths in the analysis highlights the more general issue of how to deal appropriately with deaths at different ages in constructing a measure of YLL.
As emphasized throughout this volume, data on causes of death and disability are fragmentary and are often inconsistent for many regions of the world. This is particularly true for the neonatal period and for stillbirths. One clear implication is the desirability of more and better data. Another implication is that any effort to construct an overall picture of population health must aggregate data of variable, often low, quality and completeness. In some instances this is done essentially as a political process, with various disease advocacy groups advancing their claims to policy makers and in the press. Alternatively, summary measures can be constructed systematically in a way that eliminates internal inconsistencies, describes methods carefully, and imposes the discipline of demographically derived totals into which cause-specific estimates must fit. This is the nature of our work on the global burden of disease.
STILLBIRTHS AND NEONATAL MORTALITY IN THE CONTEXT OF THE GLOBAL BURDEN OF DISEASE
This section first introduces the nomenclature used throughout the chapter. It then provides estimates of deaths and death rates that highlight stillbirths and neonatal deaths and discusses deaths by cause at different ages.
Nomenclature
This chapter follows standard usage where possible, but extends or tightens it as needed. Stillbirth refers to the birth of a dead fetus weighing more than 1,000 grams up to 0.25 years (13 weeks) prior to the expected time of birth (corresponding to 27 weeks of gestational age). Total births are the sum of the number of live births and of stillbirths. Stillbirths are conventionally divided into two categories, antepartum stillbirths, when a fetus dies before the onset of labor, and intrapartum stillbirths, when fetal death occurs during labor. The term fresh stillbirths denotes fetuses born dead but with intact skin, which are assumed to have died less than 12 hours before birth and serve as an observable surrogate measure for intrapartum stillbirths. Individuals younger than 28 days are in the neonatal period and younger than 1 year are infants. The neonatal period is divided into the early neonatal period, which refers to birth to less than 7 days old, and the remaining late neonatal period. The postneonatal period extends from 28 days to under 1 year. Child in this chapter refers to an individual from age one to under age five. (In some other usage, however, child refers to all individuals under age five).
We use standard demographic terminology to indicate death rates at different ages, that is, x q y refers to the probability that an individual aged y will die before reaching age y ϩ x and is usually estimated using cross-sectional observations of age-specific mortality rates for individual ages in the age range y to y ϩ x. Using this terminology, the mortality rate for those under one year old (or the infant mortality rate) is 1 q 0 . We extend this terminology to define the complete under one mortality rate as 1.25 q Ϫ.25 , the child mortality rate as 4 q 1 , 1 the under five mortality rate as 5 q 0 , the stillbirth rate as .25 q Ϫ.25 , the neonatal mortality rate as .077 q 0 , and the complete under five mortality rate as 5.25 q Ϫ.25 . This chapter uses age-specific mortality rates for 2001.
Numbers of Deaths and Death Rates
In 2001, approximately 10.6 million children born alive died before their fifth birthday (8.2 percent of births). Of these deaths, 3.9 million occurred during the neonatal period, that is, under the age of 28 days. Another 3.3 million stillborn children remained outside the vital registration systems of most countries (WHO 2005a) . When stillbirths are included among deaths, about half of all deaths of children under five occur under the age of 28 days. (WHO 2005a) applied to the birth numbers reported in the table. The table shows that in 2001, the high-income countries (those with a gross national income per capita of more than US $9,076 in 2002) had 11.37 million live births and the lowand middle-income countries had 118.51 million live births. Table 6 .2 provides an age breakdown of deaths among children under five, again with a breakdown by World Bank income category. Early neonatal deaths account for 75 percent of all neonatal deaths. The eight-day period encompassing intrapartum stillbirths and early neonatal deaths accounts for almost 30 percent of the 13.9 million deaths occurring under the age of five. Thus, as shown in figure 6 .1 for the low-and middle-income countries, roughly a quarter of the deaths under age five occur in each of the following categories: stillbirths, neonatal deaths, postneonatal infant deaths, and child deaths.
Three recent studies provide extensive literature reviews and model-based estimates of the number of stillbirths and neonatal deaths that extend the WHO estimates used here (WHO 2005a focus on intrapartum stillbirths and intrapartum-related neonatal deaths. Stanton and others (forthcoming) provide estimates of the number of stillbirths for 190 countries and Hill (forthcoming) provides estimates for neonatal deaths. -income  40  5  45  32  9  41  18  59  13  73  119  countries  World  2,192  1,082  3,274  2,921  974  3,896  3,762  7,658  2,948 deaths for those age five and older. In their preparatory work for chapter 3, its authors estimated cause-specific breakdowns of deaths under age five both for infant deaths and for deaths from age one through age four, that is, deaths occurring at one year of age or older but under age five, and we have used their data in this chapter. For the most part, the neonatal death categories used by CHERG align with the categories used by the GBD assessment in chapter 3; however, note the following exceptions:
• CHERG includes a pneumonia and sepsis category, which accounts for 26 percent of neonatal deaths globally and 27 percent in low-and middle-income countries. The GBD categories include respiratory infections (category I.B in our tables), which account for 1.945 million deaths worldwide in the age group 0-4. We allocate all the CHERGestimated deaths from the combined category sepsis and pneumonia to the neonatal age group's respiratory infections category in order to remain as consistent as possible with the GBD framework in chapter 3. A number of
The midpoints of their fairly wide confidence intervals accord with the numbers we use. Table 6 .3 shows death rates, expressed per 1,000 live births, that correspond to the death totals in table 6.2. Column (c), for example, shows an under one or infant mortality rate ( 1 q 0 ) for low-and middle-income countries of 64 per 1,000. Column (d) shows the effect of including stillbirths to give the complete under one mortality rate ( 1.25 q Ϫ.25 ), which is markedly higher at 89 per 1,000 live births. By including stillbirths and providing relatively fine-grained age breakdowns, table 6.3 provides a more comprehensive set of estimates of mortality rates under age five than has hitherto been available. The wide confidence interval that needs to be attached to the estimates (Stanton and others forthcoming) indicates both the need for caution when using these numbers and the importance of further research. Nevertheless, the estimates in table 6.3 are reasonable given currently available information.
Deaths by Cause
Estimates of the total number of deaths in different age groups provide a starting point for breaking those totals down into deaths by cause. This task inevitably involves some degree of arbitrariness because of problems with classifying multiple causes of death or underlying versus proximal causes. That said, available data from vital registration, sentinel surveillance, and verbal autopsy can provide reasonable approximations for most causes. Chapter 3 provides background on how this was done and generates the death by cause estimates used throughout this book.
We use the estimates from chapter 3 for deaths by cause in the newborn through age four age group and aggregate chapter 3 data on age groups over age five into a single category of Our categorization of neonatal deaths within the GBD framework has been deliberately conservative in that where interpretation was in any way uncertain, we assigned deaths to the not allocated category. We expect future efforts to be able to substantially reduce the not allocated component for both stillbirths and neonatal deaths, but doing so will require both improved empirical information and modification of the current GBD framework to include classifications important for deaths near the time of birth. Until such improvements are possible, table 6.4 provides a plausible extension of the GBD cause of death framework to include causes of infant and neonatal deaths.
THE BURDEN OF DISEASE RESULTING FROM EVENTS NEAR THE TIME OF BIRTH
This section explains the use of DALYs as a measure of the disease burden and identifies a number of problems associated with the traditional DALY formulation when dealing with events around the time of birth. It proposes a generalized formulation (which annex 6A describes more fully). The chapter then calculates the disease burden using two approaches to explore the sensitivity of GBD estimates to alternative formulations as follows:
• the current DALY formulation extended so as to value the DALY loss from a stillbirth the same as the DALY loss from a death at age 0, • a generalized DALY formulation allowing the acquisition of life potential (ALP) to be gradual rather than instantaneous.
Defining and Redefining DALYs
The DALY family of indicators measures the disease burden from the age of onset of a condition by summing an indicator of YLL due to the condition and an indicator of disabilityadjusted YLD resulting from the condition. While, in principle, the disability weights used in this adjustment could arise from any of the procedures typically used to construct qualityadjusted life years, obtaining disability weights for a large number of causes using any procedure other than the judgments of selected reference groups is currently impractical. Chapter 3 describes the methods currently used. The absence of an entry in columns a-d denotes either a value of less than 1,000 deaths or that no estimate was allocated to that entry. For columns f-k, a blank cell indicates that fewer than 1,000 deaths are attributable to the specific cause. Infant and child deaths in columns f and g are based on unreported estimates undertaken as part of the GBD study, reported in chapter 3, of the percentage of under-five deaths that were under age one. Because the sources used for neonatal deaths left a large number unallocated, it is not appropriate to calculate values of column e by subtracting column d from column f except where explicitly noted. a. WHO 2005b and others (2005) estimate that 395,000 deaths occur due to measles. Chapter 3 provides an estimate for measles deaths age zero to four of 763,000. b. Lawn, Wilczynska, and Cousens (forthcoming) for the CHERG estimate (2005) that 7 percent (260,000) of the 3.854 million global neonatal deaths occur due to tetanus, similar to the WHO and GAVI estimates of 220,000 for the year 2000. Chapter 3 provides an estimate for tetanus deaths ages zero to four of only 187,000. The (unpublished) GBD files used here to allocate deaths under age five to over and under age one allocated 52 percent of tetanus deaths to under age one. The CHERG review (Lawn, Wilczynska, and Cousens forthcoming) suggests this to be a major underestimate, and the 52 percent figure has thus here been revised upward to 90 percent. Consistent with the objectives of this chapter, GBD numbers have been used wherever possible, and the CHERG and WHO estimates are accordingly revised downward by allocating all infant tetanus deaths to the neonatal period. c. WHO 2005b and others (2005) estimate that 853,000 deaths occur due to malaria. Chapter 3 provides an estimate for malaria deaths age zero to four of 1,208,000. d. Hepatitis, tropical-cluster diseases, leprosy, dengue, Japanese encephalitis, trachoma, intestinal nematode infections, and other infectious diseases. e. Deaths for respiratory infections in the neonatal age group are those estimated by Lawn, Cousens, and Wilczynska (forthcoming) for their category sepsis or pneumonia. This number was then subtracted from the GBD number of respiratory infections between age zero and one to derive the total in column e. f. Low-birthweight deaths are those resulting from intrauterine growth retardation or preterm birth. Almost all low-birthweight deaths in the neonatal period result from preterm birth. Table 6 .4 Continued g. Lawn, Wilczynska, and Cousens (forthcoming) for the CHERG estimate that 23 percent (887,000) of the 4 million global neonatal deaths occur due to birth asphyxia. Chapter 3 of this volume provides an estimate for birth asphyxia and birth trauma deaths ages zero to four of only 739,000 globally, of which 734,000 were estimated to occur under age one. Consistent with the objectives of this chapter, GBD numbers have been used wherever possible, and the CHERG and WHO estimates are accordingly revised downward by allocating all infant birth asphyxia deaths to the neonatal period. Better data in the future will allow for improved estimates. h. Epilepsy, alcohol use disorders, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, drug use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, insomnia (primary), migraine, mental retardation attributable to lead exposure, and other neuropsychiatric disorders. i. Rheumatic heart disease, hypertensive heart disease, inflammatory heart diseases, and other cardiovascular diseases. j. Other neoplasms, endocrine disorders, sense organ diseases, genitourinary diseases, skin diseases, musculoskeletal diseases, and oral conditions. k. Poisonings, falls, fires, drownings, and other unintentional injuries. l. Violence, war, and other intentional injuries.
Low-and middle-income countries
(Continues on the following page.) Sources: WHO 2005a for columns a-d, unreported estimates undertaken as part of the GBD study, reported in chapter 3 for columns f-g, and chapter 3 of this volume. Note: The absence of an entry in columns a-d denotes either a value of less than 1,000 deaths or that no estimate was allocated to that entry. For columns f-k, a blank cell indicates that fewer than 1,000 deaths are attributable to the specific cause. Infant and child deaths in columns f and g are based on unreported estimates undertaken as part of the GBD study, reported in chapter 3, of the percentage of under five deaths that were under age one. Because the sources used for neonatal deaths left a large number unallocated, it is not appropriate to calculate values of column e by subtracting column d from column f except where explicitly noted. a. Hepatitis, tropical-cluster diseases, leprosy, dengue, Japanese encephalitis, trachoma, intestinal nematode infections, and other infectious diseases. b. This table does not attempt to partition by age the very small number of deaths from respiratory infections under age 5. c. Low-birthweight deaths are those resulting from intrauterine growth retardation or preterm birth. Almost all low-birthweight deaths in the neonatal period result from preterm birth. d. The World Health Report 2005 cites that 45 percent (19,000) of the 4 million global neonatal deaths occur due to pre-term birth. Chapter 3 of this volume provides an estimate for low birthweight deaths ages zero to four of only 10,000, of which 10,000 were estimated to occur under age one. Consistent with the objectives of this chapter, GBD numbers have been used wherever possible, and the World Health Report 2005 estimates are accordingly revised downward by allocating all low-birthweight deaths to the neonatal period. Better data in the future will allow for improved estimates. e. Epilepsy, alcohol use disorders, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, drug use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, insomnia (primary), migraine, mental retardation attributable to lead exposure, and other neuropsychiatric disorders. f. Rheumatic heart disease, hypertensive heart disease, inflammatory heart diseases, and other cardiovascular diseases. g. Other neoplasms, endocrine disorders, sense organ diseases, genitourinary diseases, skin diseases, musculoskeletal diseases, and oral conditions. h. Poisonings, falls, fires, drownings, and other unintentional injuries. i. Violence, war, and other intentional injuries. Sources: WHO 2005a for columns a-d, unreported estimates undertaken as part of the GBD study, reported in chapter 3 for columns f-g, and chapter 3 of this volume. Note: The absence of an entry in columns a-d denotes either a value of less than 1,000 deaths or that no estimate was allocated to that entry. For columns f-k, a blank cell indicates that fewer than 1,000 deaths are attributable to the specific cause. Infant and child deaths in columns f and g are based on unreported estimates undertaken as part of the GBD study, reported in chapter 3, of the percentage of under five deaths that were under age one. f. Low-birthweight deaths are those resulting from intrauterine growth retardation or preterm birth. Almost all lowbirthweight deaths in the neonatal period result from preterm birth. g. Lawn, Wilczynska, and Cousens (forthcoming) for the CHERG estimate that 23 percent (887,000) of the 4 million global neonatal deaths occur due to birth asphyxia. Chapter 3 of this volume provides an estimate for birth asphyxia and birth trauma deaths ages zero to four of only 739,000 globally, of which 734,000 were estimated to occur under age one. Consistent with the objectives of this chapter, GBD numbers have been used wherever possible, and the CHERG and WHO estimates are accordingly revised downward by allocating all infant birth asphyxia deaths to the neonatal period. Better data in the future will allow for improved estimates. h. Epilepsy, alcohol use disorders, Alzheimer's disease and other dementias, Parkinson's disease, multiple sclerosis, drug use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, insomnia (primary), migraine, mental retardation attributable to lead exposure, and other neuropsychiatric disorders. i. Rheumatic heart disease, hypertensive heart disease, inflammatory heart diseases, and other cardiovascular diseases. j. Other neoplasms, endocrine disorders, sense organ diseases, genitourinary diseases, skin diseases, musculoskeletal diseases, and oral conditions. k. Poisonings, falls, fires, drownings, and other unintentional injuries. l. Violence, war, and other intentional injuries. DALYs generate a measure of the disease burden resulting from premature mortality by integrating a discounted, ageweighted, disability-adjusted stream of life years from the age of death (see equation 6A.2 in annex 6A). The formulation within the family of DALYs previously used to empirically assess the global burden of disease specifies a constant discount rate of 3 percent per year and an age-weighting function that gives low weight to early childhood and older ages and greater weight to middle ages. This volume reports global burden of disease estimates generated using uniform age weights. Chapter 5 provides an extensive exploration of the uncertainty and sensitivity inherent in disease burden assessment, including the results of differing assumptions about age weighting and discount rates.
Deaths under age 5
To be clear about the particular form of DALY being used, the following terminology is employed throughout this volume. DALYs(r,K) are DALYs constructed using a discount rate of r percent per year and an amount of age weighting indexed by a parameter K. Two versions of the DALY are discussed at some length in chapter 5, both using a discount rate of 3 percent per year. DALYs(3,1) are DALYs generated with a discount rate of 3 percent per year and with full age weighting, that is, K ϭ 1. DALYs(3,0) are DALYs generated with a discount rate of 3 percent per year and with no age weighting, that is, K ϭ 0. This volume's results concerning the burden of disease (chapter 3) and of risk (chapter 4) are based on DALYs(3,0). Annex 6B contains tables summarizing alternative calculations of the global burden of disease, and table 6B.4 presents the chapter 3 GBD results based on DALYs(3,0), using this chapter's aggregation of causes, for age groups under five and over five as an aggregate.
This chapter extends the DALY family by modeling a concept of ALP. The intuition behind the ALP concept is that an infant (or fetus) only gradually acquires the full life potential reflected in a stream of life years beginning at birth, that is, ALP can be gradual. The ethical understanding of the concept is based on two judgments: (a) an individual life acquires value only as it acquires self-awareness, and (b) an individual life acquires additional value as it develops bonds with others. (See the discussion in Steinbock 1992 , who argues that what we label as life potential is probably acquired some time in the second trimester of pregnancy. Her position is, implicitly, that whenever it occurs, ALP is instantaneous.) To some extent, the age-weighting function of the current DALY formulation attempts to capture these judgments, and in this chapter, gradual acquisition of ALP is modeled as an alternative to age weighting. 3 Mathematically, however, ALP and age weighting are independent and can be introduced simultaneously.
Our objective in this chapter is not to provide a detailed philosophical, economic, or medical rationale for gradual ALP, but to generate and apply a straightforward mechanism that allows for it. Annex 6A describes this mechanism, which essentially consists of multiplying the DALYs conventionally generated by a factor that is less than one for younger ages. This factor is zero for an age of Ϫ13 weeks (or Ϫ0.25 years), rises to a factor value of f 0 at birth, then rises to 1 at time T. Figure 6 .2 graphs both the ALP function used later in this chapter and the special case of ALP that jumps from 0 to 1 at age 0 (instantaneous ALP). The ALP implicit in traditional DALYs is instantaneous.
Annex 6A introduces a parameter, A, that indicates the speed of ALP (see equations 6A.3 through 6A.5 for a precise definition of A). A is constructed so that for the fastest possible speed of ALP, namely, instantaneous ALP, A ϭ 1. A is bounded below by 0. This chapter extends the notation DALYs(r,K) used elsewhere in the book in two ways. First, it explicitly indicates the level of A by extending the DALY nomenclature to DALYs(r,K,A). Thus using this nomenclature, DALYs(3,0) become DALYs(3,0,1), because the standard DALY is the special case with instantaneous ALP. Second, when stillbirths are included in the range of events to be measured in the global burden of disease, this is explicitly noted in the DALY nomenclature as DALYs SB (r,K,A). Notation around YLL is similarly extended.
Explicit modeling of ALP allows not only the reflection of the ethical judgments just indicated, but also permits three instrumentally useful improvements to the current family of DALYs:
• The DALY loss from a death seconds before birth is, in the current formulation, 0; it jumps to more than 30 years at birth. The ALP formulation allows, but does not require, this discontinuity to be avoided.See column (a) of table 6.5 for values at different ages of the ALP function associated with traditional DALYs and columns (c), (d), and (e) for values of three ALP functions defined in annex 6A.
• The ALP formulation allows, but does not require, a positive DALY loss associated with stillbirths.
• The ratio of the DALY loss from a death at age 20, say, to that at birth is close to 1 for any reasonable set of parameter values in the current DALY formulation. Many people's ethical judgments would give this ratio a value substantially greater than 1. The ALP formulation allows, but does not require, these judgments. Figure 6 .3 shows how this ratio varies as a function of the age-weighting parameter (K) for values of r equal to 3 percent and 10 percent. The ratio rises only to 1.7 with full age weighting and an implausibly high discount rate of 10 percent.
Alternative Calculations of the Burden of Disease
As previously indicated, annex Our first alternative is probably the simplest way to incorporate stillbirths. It does so by having an instantaneous ALP function, as with traditional DALYs, but by having that function jump from 0 to 1 at age Ϫ13 weeks (Ϫ0.25 years) instead of at age 0. Stillbirths are then given the same DALY loss as a death at birth in generating YLL. Column (b) of table 6.5 shows values for this ALP function, which is uniformly 1. We label the YLL generated from this ALP function and a 3 percent discount rate the YLL SB (3,0,1). We label the DALYs based on this YLL as DALYs SB (3,0,1). Table 6 .6 shows values of YLL SB (3,0,1) compared with YLL(3,1) and YLL(3,0) for different ages. Annex table 6B.5 shows values for YLL SB (3,0,1) and annex table 6B.6 shows the resulting burden of disease estimates in terms of DALYs SB (3,0,1).
Our second alternative burden of disease assessment is based on gradual ALP. Equation 6A.1 in annex 6A provides our general ALP function and the text describes the meaning of its four parameters. One of the parameters, f 0 , is the value of the function at age 0. The intuitive interpretation of f 0 is that it is approximately the ratio of the YLL loss associated with a death at age 0 to that from a death at age 20. Another parameter is T, the age at which the function becomes 1. Annex 6A characterizes three alternative gradual ALPs: f 1 , f 2 , and f 3 . Figure 6 .4 shows YLL at different ages for these functions and for YLL(3,0) and YLL(3,1). columns (c), (d), and (e). We use f 2 (with A ϭ .54) to construct the disease burden estimates reported in this chapter and label the resulting YLL and DALYs as YLL SB (3,0,.54) and DALYs SB (3,0,.54). Table 6 .6 shows YLL SB (3,0,.54), which are, as intended, markedly lower than YLL SB (3,0,1) for very young ages. That is, YLL SB (3,0,.54) gives less weight to deaths near the time of birth or to deaths immediately after birth than YLL SB (3,0,1). Only a limited number of empirical studies have attempted to assess directly the views of individuals concerning deaths at different ages. In an important early study, Crawford, Salter, and Jang (1989) relate grief from a death to the concept of reproductive potential in population biology. They conclude that for several diverse human groups the relationship shows grief to be closely related to prehistoric reproductive value. Cropper, Aydede, and Portney (1994) and Johannesson and Johansson (1997) of populations of high-income countries for trade-offs between deaths in middle and older ages. All three of these studies find that people judge deaths at older middle age as much less important than deaths at younger middle age, but provide no information concerning the trade-off for deaths near the time of birth.
survey members
An Institute of Medicine (1985) review of vaccine development priorities uses infant mortality equivalence in cost-effectiveness calculations. The committee members preparing the report collectively judged that the loss from a death at age 20 should be about two times that from an infant death, well above the numbers shown in figure 6 .3 for any standard DALY. However, some preliminary trade-off studies by one of the authors of this chapter suggest a value closer to three or four times. What is clear is that no defensible estimate (or even range) is currently available, and hence the numbers we report should be viewed only as perhaps reasonable but only suggestive and as indicating the sensitivity of global burden of disease results from younger ages to better estimates of this parameter.
Annex tables 6B.7 and 6B.8 show YLL SB (3,0,.54) and DALYs SB (3,0,.54). While table 6B.7 only shows the total of DALYs for ages under five, the calculations underlying those totals reflect the age distribution of deaths under age five shown in table 6.4 and the YLL SB (3,0,.54) for deaths at different ages as shown in table 6.6.
Annex tables 6B.1, 6B.6, and 6B.8 provide three alternative assessments of the global burden of disease based on deaths by cause, on DALYs(3,0), DALYs SB (3,0,1), and DALYs SB (3,0,.54). Table 6 .4 provides estimates of deaths by cause that include stillbirths (table 6.4, column [k]). We thus have five alternative indicators of the importance of disease at different ages and from different causes. Table 6 .7 provides a summary for low-and middle-income countries of the distribution of the disease burden at different ages as assessed by these different measures. DALYs SB (3,0,1) and DALYs SB (3,0,.54) both point to the significance of stillbirths relative to DALYs(3,0), which exclude them altogether, but the gradual ALP approach of DALYs SB (3,0,.54) gives much less importance to stillbirths than DALYs SB (3,0,1) and substantially less importance to the under five burden than DALYs(3,0). Table 6 .8 provides a similar summary of how the assessed burden across groups varies with the measure used. DALYs SB (3,0,.54) give more weight to Group II (noncommunicable diseases) and Group III (injuries) causes than do DALYs(3,0), while DALYs SB (3,0,1) give less weight to these groups than DALYs(3,0). For example, DALYs SB (3,0,.54) give about a 10 percent greater weight to cardiovascular disease than does the DALY (3,0), that is, 14.2 percent versus 12.9 percent.
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CONCLUSIONS
Previous assessments of the global burden of disease have not included stillbirths or sufficiently emphasized the important causes of neonatal death. This was understandable given the intended focus of these studies. In addition, the inclusion of stillbirths would have highlighted issues about how to weight deaths at different ages that would have been difficult to incorporate into the DALY metrics being used to assess the global burden of disease. Data on the numbers of stillbirths and neonatal deaths have improved, and a recent major effort by CHERG now provides a much better picture than before of the causes of neonatal death. (Annex C describes the CHERG effort and compares its results with estimates that result from fitting the CHERG estimates into the overall death envelope of chapter 3.) This chapter proposes an approach that incorporates modeling ALP, which allows flexibility in assessing how to weight stillbirths and other early deaths in constructing aggregate measures of the disease burden. This chapter combines new information and new methods into a reassessment of the global burden of disease that is based closely on, but goes beyond, what is reported in chapter 3.
We draw the following conclusions from this exercise:
• • The inclusion of stillbirths within the standard GBD framework is now feasible, and future assessments of the global burden of disease could consider doing so. • The GBD cause structure would need relatively minor modifications to incorporate deaths at early ages. Birth asphyxia and preterm births could be separate subcategories and sepsis and pneumonia could also be included as a separate category. Rather than reporting a single burden estimate for the under five age group, the more finegrained age breakdown of table 6.4 could be used.
• The databases on numbers and causes of stillbirths and neonatal deaths require major investments so they can be improved. Undertaking a CHERG type of review of the existing literature to gain a better understanding of the causes of stillbirths is also a priority.
• The selection of a generally appropriate ALP function requires more data on preferences or trade-offs concerning deaths at different ages.
ANNEX 6A: FLEXIBLE FUNCTIONAL FORMS FOR THE ACQUISITION OF LIFE POTENTIAL
This annex provides a technical discussion of issues raised by incorporating late fetal deaths (stillbirths) into the global burden of disease, as measured within the disabilityadjusted life year (DALY) framework. One approach is simply to take the DALY loss at birth and discount back to the time of the stillbirth, indicating that there are no life years to lose before birth, but that there are still all the postpartum life years. Essentially this is the standard DALY, but with an age-weighting function equal to 0 before birth. This is feasible, but has several potential drawbacks, in particular, any reasonable discount rate (for example, 3 percent) would thence count all late fetal losses almost the same as a loss at birth. This approach yields the DALYs SB (3,0,1) measure as described in the main text, and table 6B.6 presents global burden of disease estimates using DALYs SB (3,0,1) because these are the simplest extension of DALYs(3,0). However, as with traditional DALYs, DALYs SB (3,0,1) assume instantaneous acquisition of life potential (ALP), as illustrated in figure 6.2 and discussed in the main text. Whether or not one wishes to include stillbirths in the global burden of disease, this discontinuity (at some given age) is troublesome. The purpose of this annex is to provide a flexible, yet tractable, explicit function that allows for gradual ALP.
One natural approach is to weight the YLL from outside the integral instead of from the inside (as with age weighting), that is, to create a multiplier function (the ALP function), which takes on values between 0 and 1 as a function of age, and use it to ratchet down the YLL function, potentially starting before birth. For convenience and with some regard to the known physiological underpinnings, we take this starting point in time to be the beginning of the third trimester of pregnancy. Roughly speaking, the rate of natural fetal loss becomes noticeable after the beginning of some level of consciousness during the second half of the second trimester. One could force this function to equal 1 at birth, recovering the standard DALYs from that point onward, and this will be a special case of our formulation. However, we have no definitive reason to think that ALP is necessarily complete at birth. Indeed, quite a bit of evidence suggests that in many (if not all) societies worldwide, infants are not given full status, for instance, they are not always named immediately. Thus we wish to allow for continued gradual acquisition after birth and up to some time T that signifies full standing or full ALP. Likewise, starting the acquisition only at birth but proceeding gradually afterward is perfectly possible.
Turning to the specifics, denote the ALP multiplier function by f(t), where t is measured in years and ranges from Ϫ0.25 (that is, 13 weeks before birth, the beginning of the third trimester) to T. The function is meaningfully defined for any finite value of T, though it is natural to assume that full life potential is achieved by puberty at the latest. Thus f(Ϫ0.25) ϭ 0 and f(T) ϭ 1. We let f 0 ϭ f(0) be the value at 0. Of course, starting times other than Ϫ0.25 are perfectly legitimate as well, but Ϫ0.25 is the natural choice given the standard definitions of stillbirth and the gathering and reporting of data using that definition.
We need a functional form that smoothly begins at 0 and rises to f 0 , which is at least weakly convex (following the intuition that life potential is acquired increasingly rapidly as birth is approached), and whose curvature is parametrizable. The natural choice is x ␥ with ␥ Ն 1. This has canonical endpoints of 0 and 1, where x ␥ takes on the values 0 and 1, respectively, for any ␥, so that as we change the curvature (or skewness), the endpoints remain fixed. Fitting this to our specific domain, we get x ϭ 4t ϩ 1 for Ϫ0.25 Յ t Ͻ 0. Finally, if we wish the skewness parameter to lie between 0 and 1 as well (for clarity), we can define g so that g ϭ 1͞(1 Ϫ g) for 0 Յ g Ͻ 1. This yields f -(t) ϭ f 0 (4t ϩ 1) 1͞(1Ϫg) for Ϫ0.25 Յ t Ͻ 0. Thus g ϭ 0 produces a straight line (zero curvature), while g ϭ 1 (defined by fiat) is infinitely skewed: 0 until birth and then jumping to f 0 .
For t Ն 0, we consider the symmetric version of the same polynomial, that is, 1 Ϫ (1 Ϫ x) ␤ . Again we fit this to our domain, namely, from t ϭ 0 to t ϭ T, and define b so that b ϭ 1͞(1 Ϫ b) for the skewness. This yields f ϩ (t)
We check that indeed f ϩ (0) ϭ f 0 and f ϩ (T) ϭ 1 according to this formula for any 0 Յ ␤ Յ 1. If T ϭ 1, the formula simplifies to f + (t) ϭ 1 Ϫ (1 Ϫ f 0 )(1 Ϫ t) 1͞(1Ϫb) . This leaves four parameters: f 0 , T, g, and b. We can additionally impose g ϭ b if we wish, but this is unnecessary.
Summarizing, the function we use for ALP is
If f D (t) is the standard DALY formulation (whether or not age weighting or discounting is used), then g ϭ b ϭ 1 f Ϫ (t) ϭ f 0 (4t ϩ 1) 1͞(1Ϫg) (for Ϫ0.25 Յ t Ͻ 0)
(that is, discontinuous jumps around birth from 0 to 1) and f D 0 ϭ 1, so that technically at age 0 the value is already 1 (so the discontinuity is on the left side of age 0 only). Given these parameters, T is immaterial, because the function achieves its maximum immediately. However, the fact that we can replicate the standard DALY means that the gradual acquisition function does indeed generalize it. Combining these equations with the standard definition of DALYs, the total loss L(a) for a death at age a Ն Ϫ0.25 is
where ␤ is the age-weighting parameter (typically 0.04) if age weighting is used, r is the discount rate (typically 0.03), s a (x) is the survival probability for reaching age x Ն a conditional on having reached age a, and C is the normalization parameter for the age weights (C ϭ 0.16243, see the discussion in chapter 5).
The normalization parameter C in equation (6A.2) was chosen so that the total global burden of disease would be the same with and without age weighting. The index of age weighting referred to in the main text, K, is generated by having a weighted average-with weights of K and (1 Ϫ K), where 0 Յ K Յ 1-of loss functions L(a) that result from equation (6A.2) with the indicated values of ␤ and C and a loss function assuming uniform age weights. That this is at least approximately the case is apparent from figure 6.4b, where the two functions cross at about age 40. Clearly this will not be true when any of the acquisition functions are used, because they reduce the YLL burden at younger ages with no corresponding increase elsewhere, leading to a reduced total burden as measured by absolute DALY levels.
Note, however, that the total burden is no longer the same even for DALYs(3,0) and DALYs(3,1), because the specific value of C was calibrated to 1990 morbidity and mortality statistics. One can readily imagine more neutral (and invariant) normalizations, such as requiring a constant integral over age of death for each of these YLL functions, or perhaps weighting this integral using an idealized survival table. Any variant along these lines would raise the total level of DALYs(3,0,.54) relative to both DALYs(3,0) and DALYs(3,1). Of course, we are for the most part interested only in the relative burden across ages or disease categories, so the absolute totals are of secondary importance.
Finally, to somewhat simplify the number of parameters in the ALP function, we introduce a notion of speed of acquisition, A. then f ϭ 1 thereafter and the speed A is in some sense as large as possible. To generalize this idea, we look at the total area between the ALP function f(t) and the constant function 1.
Formally, this area is given by the integral of 1 Ϫ f(t), evaluated from t 0 to T, where t 0 is the first t s u c h that f(t) Ͼ 0. It is thus typically either Ϫ0.25 or 0, depending on whether we are including stillbirths. Call this integral I:
Substituting the second part of equation (6A.1), we can evaluate this integral as
Normalizing so that the speed A lies between 0 and 1 (and higher values denote faster acquisition), we define
For example, for b ϭ 0.7 (a typical value) and t 0 ϭ 0, we obtain a simple formula for the speed parameter A, encapsulating the acquisition function in a single number:
There is still a trade-off between T and f 0 , that is, the relationship between the underlying parameters and A is not one-to-one. A single value for A could have arisen from multiple combinations parameter values, but it still serves as a useful summary statistic. Figure 6A.1 graphs (as a function of T, fixing b ϭ 0.7 and t 0 ϭ 0) the value of f 0 that yields various specified acquisition speeds A. The analogous figure 6.3 shows less variability in this ratio.
We evaluate three specifications (parameter choices) for the acquisition function. These are, in order of value at birth: Source: Chapter 3 of this volume. Note: A blank cell indicates that fewer than 1,000 deaths are attributable to the specific cause. a. Hepatitis, tropical-cluster diseases, leprosy, dengue, Japanese encephalitis, trachoma, intestinal nematode infections, and other infectious diseases. b. Epilepsy, alcohol use disorders, Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, drug use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, insomnia (primary), migraine, mental retardation attributable to lead exposure, and other neuropsychiatric disorders. c. Rheumatic heart disease, hypertensive heart disease, inflammatory heart diseases, and other cardiovascular diseases. d. Other neoplasms, endocrine disorders, sense organ diseases, genitourinary diseases, skin diseases, musculoskeletal diseases, and oral conditions. e. Poisonings, falls, fires, drownings, and other unintentional injuries. f. Violence, war, and other intentional injuries. Source: Chapter 3 of this volume. Note: A blank cell indicates that fewer than 1,000 deaths are attributable to the specific cause. a. Hepatitis, tropical-cluster diseases, leprosy, dengue, Japanese encephalitis, trachoma, intestinal nematode infections, and other infectious diseases. b. Epilepsy, alcohol use disorders, Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, drug use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, insomnia (primary), migraine, mental retardation attributable to lead exposure, and other neuropsychiatric disorders. c. Rheumatic heart disease, hypertensive heart disease, inflammatory heart diseases, and other cardiovascular diseases. d. Other neoplasms, endocrine disorders, sense organ diseases, genitourinary diseases, skin diseases, musculoskeletal diseases, and oral conditions. e. Poisonings, falls, fires, drownings, and other unintentional injuries. f. Violence, war, and other intentional injuries. Source: Chapter 3 of this volume. Note: A blank cell indicates that fewer than 1,000 deaths are attributable to the specific cause. a. Hepatitis, tropical-cluster diseases, leprosy, dengue, Japanese encephalitis, trachoma, intestinal nematode infections, and other infectious diseases. b. Epilepsy, alcohol use disorders, Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, drug use disorders, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, insomnia (primary), migraine, mental retardation attributable to lead exposure, and other neuropsychiatric disorders. c. Rheumatic heart disease, hypertensive heart disease, inflammatory heart diseases, and other cardiovascular diseases. d. Other neoplasms, endocrine disorders, sense organ diseases, genitourinary diseases, skin diseases, musculoskeletal diseases, and oral conditions. e. Poisonings, falls, fires, drownings, and other unintentional injuries. f. Violence, war, and other intentional injuries. 
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